Literature DB >> 29084866

Autocrine Interleukin-10 Mediates Glucagon-Like Peptide-1 Receptor-Induced Spinal Microglial β-Endorphin Expression.

Hai-Yun Wu1, Xue-Qi Tang1, Xiao-Fang Mao1, Yong-Xiang Wang2.   

Abstract

The glucagon-like peptide-1 (GLP-1) receptor agonist exenatide stimulates microglial β-endorphin expression and subsequently produces neuroprotection and antinociception. This study illustrated an unrecognized autocrine role of IL-10 in mediation of exenatide-induced β-endorphin expression. Treatment with exenatide in cultured primary spinal microglia concentration dependently stimulated the expression of the M2 microglial markers IL-10, IL-4, Arg 1, and CD206, but not the M1 microglial markers TNF-α, IL-1β, IL-6, or CD68. Intrathecal exenatide injection also significantly upregulated spinal microglial expression of IL-10, IL-4, Arg 1, and CD206, but not TNF-α, IL-1β, IL-6, or CD68. Intrathecal injection of exenatide stimulated spinal microglial expression of IL-10 and β-endorphin in neuropathic rats. Furthermore, treatment with IL-10 (but not IL-4) stimulated β-endorphin expression in cultured primary microglia, whereas treatment with β-endorphin failed to increase IL-10 expression. The IL-10-neutralizing antibody entirely blocked exenatide-induced spinal microglial expression of β-endorphin in vitro and in vivo and fully blocked exenatide mechanical antiallodynia in neuropathic rats. Moreover, specific cAMP/PKA/p38 signal inhibitors and siRNA/p38β, but not siRNA/p38α, completely blocked exenatide-induced IL-10 expression in cultured primary microglia. Knock-down of IL-10 receptor-α mRNA using siRNA fully inhibited exenatide-induced spinal microglial β-endorphin expression and mechanical antiallodynia in neuropathy. Exenatide also markedly stimulated phosphorylation of the transcription factor STAT3 in cultured primary microglia and β-endorphin stimulation was completely inhibited by the specific STAT3 activation inhibitor. These results revealed that IL-10 in microglia mediated β-endorphin expression after GLP-1 receptor activation through the autocrine cAMP/PKA/p38β/CREB and subsequent IL-10 receptor/STAT3 signal pathways.SIGNIFICANCE STATEMENT Activation of GLP-1 receptors specifically and simultaneously stimulates the expression of anti-inflammatory cytokines IL-10 and IL-4, as well as the neuroprotective factor β-endorphin from microglia. GLP-1 receptor agonism induces β-endorphin expression and antinociception through autocrine release of IL-10. Activation of GLP-1 receptors stimulates IL-10 and β-endorphin expression subsequently through the Gs-cAMP/PKA/p38β/CREB and IL-10/IL-10 receptor-α/STAT3 signal transduction pathways.
Copyright © 2017 the authors 0270-6474/17/3711701-14$15.00/0.

Entities:  

Keywords:  GLP-1 receptor; IL-10; autocrine; microglia; spinal cord; β-endorphin

Mesh:

Substances:

Year:  2017        PMID: 29084866      PMCID: PMC6705741          DOI: 10.1523/JNEUROSCI.1799-17.2017

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  20 in total

1.  Involvement of d-amino acid oxidase in cerebral ischaemia induced by transient occlusion of the middle cerebral artery in mice.

Authors:  Hao Liu; Meng-Jing Zhao; Zi-Ying Wang; Qiao-Qiao Han; Hai-Yun Wu; Xiao-Fang Mao; Yong-Xiang Wang
Journal:  Br J Pharmacol       Date:  2019-07-15       Impact factor: 8.739

Review 2.  Neuroinflammation in Parkinson's Disease - Putative Pathomechanisms and Targets for Disease-Modification.

Authors:  Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip
Journal:  Front Immunol       Date:  2022-05-18       Impact factor: 8.786

3.  The glucagon-like peptide-1 receptor agonist reduces inflammation and blood-brain barrier breakdown in an astrocyte-dependent manner in experimental stroke.

Authors:  Yilong Shan; Sha Tan; Yinyao Lin; Siyuan Liao; Bingjun Zhang; Xiaodong Chen; Jihui Wang; Zhezhi Deng; Qin Zeng; Lei Zhang; Yuge Wang; Xueqiang Hu; Wei Qiu; Lisheng Peng; Zhengqi Lu
Journal:  J Neuroinflammation       Date:  2019-11-28       Impact factor: 8.322

4.  Cynandione A Alleviates Neuropathic Pain Through α7-nAChR-Dependent IL-10/β-Endorphin Signaling Complexes.

Authors:  Qiao-Qiao Han; Min Yin; Zi-Ying Wang; Hao Liu; Jun-Ping Ao; Yong-Xiang Wang
Journal:  Front Pharmacol       Date:  2021-01-27       Impact factor: 5.810

5.  Bulleyaconitine A Inhibits Morphine-Induced Withdrawal Symptoms, Conditioned Place Preference, and Locomotor Sensitization Via Microglial Dynorphin A Expression.

Authors:  Meng-Jing Zhao; Mi-Ya Wang; Le Ma; Khalil Ali Ahmad; Yong-Xiang Wang
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

6.  Rae1 drives NKG2D binding-dependent tumor development in mice by activating mTOR and STAT3 pathways in tumor cells.

Authors:  Peiyan Zhao; Lei Yang; Xin Li; Wenting Lu; Fangjie Lu; Shengnan Wang; Ying Wang; Li Hua; Cuiyun Cui; Boqi Dong; Yongli Yu; Liying Wang
Journal:  Cancer Sci       Date:  2020-05-16       Impact factor: 6.716

7.  Loss of Microglia and Impaired Brain-Neurotrophic Factor Signaling Pathway in a Comorbid Model of Chronic Pain and Depression.

Authors:  Cuizhen Zhu; Jinjie Xu; Yezhe Lin; Peijun Ju; Dongxia Duan; Yanjia Luo; Wenhua Ding; Shengnan Huang; Jinghong Chen; Donghong Cui
Journal:  Front Psychiatry       Date:  2018-10-04       Impact factor: 4.157

8.  The spinal microglial IL-10/β-endorphin pathway accounts for cinobufagin-induced mechanical antiallodynia in bone cancer pain following activation of α7-nicotinic acetylcholine receptors.

Authors:  Evhy Apryani; Usman Ali; Zi-Ying Wang; Hai-Yun Wu; Xiao-Fang Mao; Khalil Ali Ahmad; Xin-Yan Li; Yong-Xiang Wang
Journal:  J Neuroinflammation       Date:  2020-02-29       Impact factor: 8.322

Review 9.  Glucagon-Like Peptide-1 (GLP-1) in the Integration of Neural and Endocrine Responses to Stress.

Authors:  Yolanda Diz-Chaves; Salvador Herrera-Pérez; Lucas C González-Matías; José Antonio Lamas; Federico Mallo
Journal:  Nutrients       Date:  2020-10-28       Impact factor: 5.717

Review 10.  Opioid and neuroHIV Comorbidity - Current and Future Perspectives.

Authors:  Sylvia Fitting; MaryPeace McRae; Kurt F Hauser
Journal:  J Neuroimmune Pharmacol       Date:  2020-09-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.